Novel Sorrento CAR-T technology a potential “game-changer
Company envisions the development and IND filings of multiple “next-frontier” CAR-T programs in 2018 and beyond, which will position the company as a potential major player in the fast-growing CAR-T space of immunotherapies against cancers.
Sorrento Therapeutics' Dr Henry Ji, Chairman & CEO will share recent Sorrento developments and company information in a panel discussion of “R&D Trends: What's Changed in the Pharma Pipeline?” (Saturday, 6 January 3:50 - 4:20 pm PST) in the upcoming “East/West CEO” conference at the Four Seasons Hotel in San Francisco, CA. During the panel discussion, Dr Ji will present the development of a proprietary non-viral chimeric antigen receptor (CAR)-T technology that may fundamentally alter the way that CAR constructs can be integrated into T cells.
This novel Sorrento CAR-T technology has already been utilized preclinically to generate CD38 CAR-T and CD19 CAR-T cells. These CAR-T cells have been evaluated and compared against CAR-T cells generated using current retrovirus transduction methods. Data suggest that the non-virally generated CAR-T cells performed similarly to retrovirally-transduced CAR-T cells with regards to CAR expression, cytokine production, and cytotoxicity against target-expressing tumor cells.
This innovative non-viral CAR-T technology may offer several potential benefits compared with existing virus-based technology using CAR gene-encoding lentivirus, retrovirus or adeno-associated virus (AAV) to introduce CAR constructs into healthy donor (allogeneic) or cancer patient (autologous) T cells. These potential advantages of Sorrento’s non-viral CAR-T technology include
Sorrento is planning on applying its innovative non-viral CAR-T technology to CAR-T programs for multiple hematological and solid tumor indications, including but not limited to: multiple myeloma, lymphoma, liver cancer, sarcoma, pancreatic cancer and glioma. Utilizing the vast portfolio of target-specific, fully human monoclonal antibodies discovered from its proprietary G-MAB library, Sorrento envisions the development and IND filings of multiple “next-frontier” CAR-T programs in 2018 and beyond, which will position the company as a potential major player in the fast-growing CAR-T space of immunotherapies against cancers.
“Building on our preclinical and clinical experience in CAR-T cell manufacturing with our “state-of-the-art” cGMP facilities, and looking at the next frontier, we are excited to share this robust development of non-viral CAR-T technology for both autologous and allogeneic CAR-T therapies. This new “game-changer” technology may translate into faster development timelines, more cost-effective cGMP manufacturing and possible removal of the regulatory requirement to follow patients for 15 years post treatment,” stated Dr. Henry Ji. “We also have obtained preclinical data suggesting that cord blood T cells are a potentially rich and valuable “off-the-shelf” T cell source, enabling allogeneic CAR-T therapy. Working with our strategic partner, Celularity, Inc.1, Sorrento intends to develop multiple, potentially paradigm-shifting allogeneic CAR-T programs for hematological and solid tumor indications with high unmet medical need.”
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance